BridgeBio Oncology Therapeutics, Inc.
corporate_fare Company Profile
BridgeBio Oncology Therapeutics, Inc. (NASDAQ:BBOT) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 19 items for BBOT at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-10, rated 7/10. Across its 19 most recent items scored 7 or higher, the top rating is 9/10, with 13 rated 8 or above. Recent SEC coverage for BBOT spans 10-Q, 8-K, 424B3, 10-K.
Recent high-impact activity:
- BBOT Q3 10-Q: Loss Narrows to $34.2M, Cash $315.3M, Prior EPS Restated
- BBOT Q3 Loss Narrows to $34.2M; Cash Runway Extended Into 2029
- BBOT Reports 75% ORR for BBO-8520 + Pembrolizumab in G12C Inhibitor-Experienced NSCLC
- BBOT Q2 2026: Net Loss Widens to $56.5M as Pipeline Spending Ramps; Cash Runway into 2028
- BBOT Posts $56.5M Q2 Loss, Extends Cash Runway into 2028, and Advances KRAS Pipeline
Financial Snapshot
Short Interest & Short Volume
5.10 days to coverFINRA reported short interest of 3,468,496 shares in BBOT as of the October 30, 2026 settlement, a 9.8% decrease from the prior period — about 5.1 days to cover at its recent average daily volume. On November 20, 2026, 51.7% of BBOT volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
Moderate riskFiling-implied dilution signals for BBOT, detected from its recent SEC filings.
$500M Universal Shelf Registered · $200M ATM Program Established
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →